Skip to main content
OpenTrials
Completed

NCT Number: NCT02638467

Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy

Patients newly diagnosed with chronic phase chronic myeloid leukemia undergo treatment with TK inhibitors (TKI). A possible cause of TK failure is represented by the insufficient recovery of normal Ph- hematopoiesis during TKI treatment, with consequent severe cytopenias that limit TKI adequate administration. Although rare, this event happens in a proportion of 4-5% of CML patients. Our hypothesis is to circumvent this peculiar condition by providing a normal hematopoiesis from a HLA-matched donor (Human Leukocyte Antigen). The transplant procedure is therefore intended in providing a sustained hematopoiesis that will allow an early treatment with an adequate dosing of TKI. The transplant procedure planned in our study is built on all available evidences to provide the lowest incidence of acute and chronic GvHD (Graft-versus-host disease). Therefore, a bone marrow will be the preferential source and a GvHD prophylaxis based on Anti-thrombocyte globulin (ATG) and Cyclosporine/Methotrexate will be used according to standard current experience in the field of family and unrelated donors. The pre-transplant TKI will be continued until aplasia will develop, in order to decrease the tumor load as much as possible.The use of TKIs shortly after transplant carries the risk of inhibiting the newly transplanted hematopoietic cells, as Kit, an important kinase in normal bone marrow cells, is frequently blocked by Abl inhibitors. The use of bosutinib as post-transplant therapy is justified by the lack of Kit inhibition that distinguishes bosutinib from all other TKIs, and which could allow a minimal inhibitory activity against the transplanted normal bone marrow.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Leukemia BCR-ABL Positive Bronchial Diseases Bronchiolitis Bronchiolitis Obliterans Bronchiolitis Obliterans Syndrome Bronchitis Chronic Graft vs Host Disease Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Lung Diseases Lung Diseases, Obstructive Myelogenous Neoplasms Neoplasms by Histologic Type Organizing Pneumonia Respiratory Tract Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

ASST-Monza, Monza, Italy/MB, Italy

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Chronic Myeloid Leukaemia -CML- in chronic phase (CP)
  • Failure to achieve at least a Major Cytogenetic Response (MCyR) after a minimum of 18 months of TKIs treatment
  • Inability to tolerate 3 months of uninterrupted full dose TKIs therapy due to hematological toxicity
  • A minimum of three treatment interruptions due to hematological toxicity Availability of a HLA-identical related donor (Matched Related Donor, MRD)
  • Availability of unrelated donor (Matched Unrelated Donor, MUD) satisfying the criteria of a 10/10 antigen match at (Human Leukocyte Antigen) HLA-A, -B, -C and - DRB1, -DQB1 at high resolution typing, or 9/10 with a permissive - DP disparity according to Fleischhauer model (Crocchiolo et al, Blood 2009)
  • Target graft size (bone marrow):
  • bone marrow: > 3 x 106 CD34+ cells/kg BW recipient or > 3 x 108 nucleated cells/kg BW
  • Karnofsky Index > 80 %
  • Age ≥18 and ≤70 years
  • Adequate contraception in female patients of child-bearing potential
  • Written informed consent

Exclusion criteria

  • Secondary malignancies
  • A hematopoietic cell transplantation-specific comorbidity index (Sorror et al Appendix C) > 4
  • Known and manifested malignant involvement of the Central Nervous System (CNS)
  • Active infectious disease
  • Active human immunodeficiency virus (HIV), Hepatitis B virus (HBV) or Hepatitis B virus (HCV) infection
  • Impaired liver function (Bilirubin > upper normal limit; Transaminases > 3.0 x upper normal limit)
  • Impaired renal function (Creatinine-clearance < 60 ml/min; Serum Creatinine > 1.5 x upper normal limit).
  • Pleural effusion or ascites > 1.0 L
  • Pregnancy or lactation
  • Known hypersensitivity to Busilvex and/or fludarabine 11 Non-co-operative behaviour or non-compliance 12 Psychiatric diseases or conditions that might impair the ability to give informed consent

Treatment and study plan

Bosutinib

Drug

Subjects will receive 400mg of bosutinib once daily from day +30 after transplant, by mouth with food, preferably in the morning. Bosutinib will also be administered from day at least -45 to day -15 to assess the sensitivity of patient CML to this TKI.

Other names: Bosulif, SKI-606

Bone Marrow Transplant

Procedure

Samples of the unrelated stem cell graft shall be characterised with respect to the number of CD34 positive cells per kg body weight of the recipient.

The number of transplanted CD34 positive cells per kg body weight (BW) of the recipient shall be recorded in the Case Report Form (CRF). If the transplant was cryopreserved the number of viable CD34 positive cells has to be determined after thawing and documented.

The goal is to transplant > 3 x 106 CD34+ cells/kg BW recipient from bone marrow or > 3 x 108 nucleated cells/kg BW recipient from bone marrow

Bone Marrow cells

Drug

Primary outcomes

  1. Efficacy as assessed by the percentage of patients with Complete Cytogenetic Response (CCyR)

    Time frame: 12 months

    The percentage of patients with Complete Cytogenetic Response (CCyR) will be calculated as the complement to the percentage of failures on the total number of patients treated, where failure includes the following events: no engraftment, death within 12 months, no CCyR at 12 months.

Secondary outcomes

  1. Overall Survival

    Time frame: 12 months

  2. Percentage of patients with engraftment

    Time frame: 12 months

  3. percentage of patients with complete chimerism (95%)

    Time frame: Day +28, +56 and +100

  4. Evaluation of Major Cytogenetic Response (MCyR)

    Time frame: 12 months

    Major Cytogenetic Response (MCyR) is < 36% Ph+ metaphases

  5. Evaluation of molecular responses

    Time frame: 12 months

    Molecular response is defined

    • Complete: if there is undetectable BCR-ABL transcript
    • Major: if ratio BCR/ABL <= 0.1% on International Scale

  6. Relapse incidence (RI)

    Time frame: 12 months

  7. Incidence of non-relapse mortality (NRM)

    Time frame: Within day +28 and +360

  8. Incidence and severity of acute and chronic graft vs. host disease (GvHD)

    Time frame: 12 months

  9. Quality of Life (QoL)

    Time frame: 12 months

    Evaluation of QoL with EQ-5D-5L (Italian - Version 2) and FACT-Leu (Italian -Version 4)

  10. Overall Survival (OS)

    Time frame: 36 months

    2 years after transplantation of the last patient included (this is intended to allow evaluations of all expected major molecular responses)

  11. Progression Free Survival (PFS)

    Time frame: 36 months

    2 years after transplantation of the last patient included (this is intended to allow evaluations of all expected major molecular responses)

  12. Relapse Incidence (RI)

    Time frame: 36 months

    2 years after transplantation of the last patient included (this is intended to allow evaluations of all expected major molecular responses)

  13. Chronic Graft-versus-host Disease (cGvHD)

    Time frame: 36 months

    2 years after transplantation of the last patient included (this is intended to allow evaluations of all expected major molecular responses)

Sponsors and collaborators

Lead sponsor

University of Milano Bicocca

Other

Collaborators

  • IRCCS San Raffaele

Registry information

Official study title

Allogeneic Haematopoietic Stem Cell Transplantation From a Matched Donor in Patients With Chronic Myeloid Leukemia Failing to Gain Normal Hemopoiesis Under TKIs Therapy

Important dates

Study start
2015
Primary completion
2018
Study completion
2020
First posted
Dec 23, 2015
Registry last updated
Nov 5, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.